Lycopene
Clinical Studies
How strong is the evidence that lycopene supplementation can modify biomarkers of oxidative damage and DNA repair in human lymphocytes?
Selection of surrogate endpoint biomarkers to evaluate the efficacy of lycopene/tomatoes for the prevention/progression of prostate cancer.
Intermediate biomarkers of lycopene/tomato effects in high-risk prostatic tissue.
How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia?
Are there adverse effects of lycopene exposure?
Tomatoes or lycopene: a role in prostate carcinogenesis?
Can smoke-exposed ferrets be utilized to unravel the mechanisms of action of lycopene?
Lycopene effects on rat normal prostate and prostate tumor tissue.
What can pharmacokinetic models tell us about the disposition of lycopene and the potential role of lycopene in cancer prevention?
How do nutritional and hormonal status modify the bioavailability, uptake, and distribution of different isomers of lycopene?
What are typical lycopene intakes?
How can the metabolomic response to lycopene (exposures, durations, intracellular concentrations) in humans be adequately evaluated?
Directions for future epidemiological research in lycopene and prostate cancer risk.
Variations in lycopene blood levels and tomato consumption across European countries based on the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature.
Executive summary report.
An improved HPLC method for determination of carotenoids in human serum.
The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies.
Lycopene, tomatoes, and coronary heart disease.
Combination of S-allylcysteine and lycopene induces apoptosis by modulating Bcl-2, Bax, Bim and caspases during experimental gastric carcinogenesis.
Page 12 of 25
